GlassScriptPhysician profile
Lyudmila Shvets
NPI 1922379890
$1,718.43
in general payments reported to CMS, 2019-2025
9 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2021: $52.01 · 2022: $280 · 2023: $125 · 2024: $263 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $762.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $663.23 | 2021-2025 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.36 | 2019-2022 | |
| Lilly USA, LLC | $255.88 | 2019 | |
| Beta Bionics, INC. | $129.43 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Novo Nordisk INC | $125.00 | 2019 | |
| Madrigal Pharmaceuticals | $122.63 | 2025 | Rezdiffra |
| Dexcom, INC. | $24.23 | 2021 | |
| Astellas Pharma US INC | $20.07 | 2025 | Veozah |
| Cequr Corporation | $10.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyudmila Shvets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.